The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa after successfully treated acute or intermittent infection.
Disease: Cystic fibrosis
Study phase: III
ECRIN support role: Advice and information
Monitoring
Local pharmacovigilance
Regulatory and ethical submission
Study/trial status: Recruitment/follow-up
Expected patient number: 180 patients
Sponsor: Mukoviszidose Institut gGmbH
Sponsor type: Academic
Principal investigator (PI): Antje Schuster
Current participating countries: Austria, Belgium, France, Germany, Hungary, Italy, Poland, Spain, Sweden
Trial identifier(s): NCT NCT01455675
EudraCT 2011-000801-39